ACTON, Mass.--(BUSINESS WIRE)--Neuroptix Corporation today announced that it has been granted a $1 million milestone payment under its previously announced Alzheimer’s Disease diagnostic collaboration with Merck & Co., Inc.
The collaboration, announced in December 2006, calls for Neuroptix to provide Merck with access to its laser eye scanning technologies, which in preclinical studies has detected Alzheimer’s-related amyloid protein aggregates in the lens of the eye. The quantitative technique has the potential for early detection and monitoring of Alzheimer’s Disease progression.
